Analyzing...
Loading company...
Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. The company is headquartered in Mumbai, Maharashtra and currently employs 26,615 full-time employees. The firm operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. The firm's product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The firm's geographical segments include India, the United States, South Africa, and Rest of the World. The firm has its network of manufacturing, trading and other incidental operations in India and International markets. The firm has approximately 47 manufacturing sites.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹28,163 Cr revenue.
COGS 33.9%, employees 19.1%.
“zero to six months...two big respiratory launches...expect to be the sole generic in those for a substantial period of time”
“two products...could be one of the largest products for the company...ballpark in that top two or top three product type of a profile for revenue”
“quarterly revenue of INR 7,074 crore, which is flat Y o Y.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 11.3%▲ | 10.3% |
| ROCE | 14.9%▲ | 13.7% |
| Net Margin | 13.4%▲ | 7.6% |
| EBITDA Margin | 22.3%▲ | 15.4% |
| Debt To Equity | 0.01x▼ | 0.15x |
| Rev Growth 3yr | 7.7%▼ | 10.0% |
| EPS Growth 3yr | 11.4%▼ | 16.0% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹28,163 Cr +2.2% | ₹27,548 Cr +6.9% | ₹25,774 Cr +13.3% | ₹22,753 Cr +4.5% | ₹21,763 Cr +13.6% | ₹19,160 Cr +11.8% | ₹17,132 Cr +4.7% | ₹16,362 Cr |
| Other Income | ₹882 Cr +2.3% | ₹862 Cr +15.4% | ₹747 Cr +57.0% | ₹475 Cr +69.3% | ₹281 Cr +5.6% | ₹266 Cr -22.7% | ₹344 Cr -27.8% | ₹477 Cr |
| Total Income | ₹29,045 Cr +2.2% | ₹28,409 Cr +7.1% | ₹26,521 Cr +14.2% | ₹23,229 Cr +5.4% | ₹22,044 Cr +13.5% | ₹19,426 Cr +11.2% | ₹17,476 Cr +3.8% | ₹16,839 Cr |
| COGS | ₹9,549 Cr +6.9% | ₹8,929 Cr +1.2% | ₹8,820 Cr +6.9% | ₹8,252 Cr -2.9% | ₹8,496 Cr +15.6% | ₹7,352 Cr +22.7% | ₹5,991 Cr +3.6% | ₹5,784 Cr |
| ₹23,545 Cr +9.1% | ₹21,589 Cr +4.7% | ₹20,624 Cr +8.5% | ₹19,008 Cr +3.5% | ₹18,369 Cr +13.8% | ₹16,136 Cr +5.5% | ₹15,298 Cr +3.6% | ₹14,760 Cr | |
| Profit Before Tax | ₹5,224 Cr -23.4% | ₹6,821 Cr +19.6% | ₹5,702 Cr +41.2% | ₹4,038 Cr +15.6% | ₹3,493 Cr +6.2% | ₹3,290 Cr +51.0% | ₹2,178 Cr +4.8% | ₹2,079 Cr |
| Exceptional Items | (₹276 Cr) | ₹0.00 Cr +100.0% | (₹195 Cr) -6.8% | (₹182 Cr) -0.2% | (₹182 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹1,354 Cr -11.5% | ₹1,530 Cr -1.1% | ₹1,547 Cr +28.6% | ₹1,203 Cr +28.8% | ₹934 Cr +5.1% | ₹889 Cr +40.8% | ₹631 Cr +10.8% | ₹570 Cr | |
| Net Profit | ₹3,862 Cr -26.7% | ₹5,269 Cr +26.9% | ₹4,154 Cr +46.6% | ₹2,833 Cr +11.2% | ₹2,547 Cr +6.6% | ₹2,389 Cr +59.3% | ₹1,500 Cr +0.5% | ₹1,492 Cr |
| Profit (Owners) | ₹3,879 Cr -26.4% | ₹5,273 Cr +27.9% | ₹4,122 Cr +47.1% | ₹2,802 Cr +11.3% | ₹2,517 Cr +4.7% | ₹2,405 Cr +55.5% | ₹1,547 Cr +1.2% | ₹1,528 Cr |
| Minority Interest | (₹17 Cr) -426.8% | (₹3 Cr) ↓ Decline | ₹32 Cr +3.8% | ₹31 Cr +3.6% | ₹30 Cr ↑ Recovery | (₹16 Cr) +65.2% | (₹47 Cr) -33.3% | (₹35 Cr) |
| Other Comprehensive Income | ₹688 Cr +214.5% | ₹219 Cr ↑ Recovery | (₹121 Cr) ↓ Decline | ₹138 Cr -64.1% | ₹384 Cr +137.6% | ₹161 Cr ↑ Recovery | (₹129 Cr) +55.4% | (₹290 Cr) |
| EPS | ₹48.03 | ₹65.28 | ₹51.05 | ₹34.71 | ₹31.19 | ₹29.82 | ₹19.18 | ₹18.96 |
| Diluted Shares | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr |
| Profit Or Loss Of Associates | (₹8 Cr) +63.2% | (₹22 Cr) | (₹2 Cr) +38.8% | (₹3 Cr) +79.7% | (₹13 Cr) -0.2% | (₹13 Cr) +73.1% | (₹47 Cr) -176.4% | (₹17 Cr) |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Cipla Limited has informed the Exchange regarding allotment of 7850 securities pursuant to ESOP/ESPS at its meeting held on July 31, 2026
Cipla Limited has informed the Exchange regarding 'Cipla Receives U.S. FDA Approval for Generic Advair Diskus®'.
Cipla Limited has informed the Exchange about Transcript
Cipla Limited has informed the Exchange about Copy of Newspaper Publication of the unaudited financial results for the quarter ended 30th June, 2026.
Cipla Limited has informed the Exchange about Link of Recording
Cipla Limited has informed the Exchange that the Board has approved the changes in the Key Managerial Personnels (KMPs) and Officers authorised under Regulation 30(5) of the SEBI Listing Regulations.
Cipla Limited has informed the Exchange regarding 'Grant Of Stock Options and Employee Stock Appreciation Rights'.
Cipla Limited has informed the Exchange about change in management.
Cipla Limited has informed the Exchange regarding Outcome of Board Meeting held on July 23, 2026.
Cipla Limited has informed the Exchange regarding a press release dated July 23, 2026, titled 'Q1 FY27 Results'
Cipla Limited has informed the Exchange about Investor Presentation
Cipla Limited has submitted to the Exchange, the financial results for the period ended June 30, 2026.
Cipla Limited has informed the Exchange about USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA
Cipla Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Cipla Limited has informed the Exchange about ESG Rating.